Efficacy and safety of fumaric acid esters in young patients aged 10 to 17 years with moderate-to-severe plaque psoriasis – A randomised, double-blinded, placebo-controlled trial.

In Dermatology
by ClinOwl December 17, 2020

Apart from three biologics, no systemic drugs are approved in Europe for children with moderate-to-severe psoriasis. Retrospective observational studies showed promising results for fumaric acid esters (FAE) in this setting.To […]

U.S. Burden of Skin and Subcutaneous Diseases Increasing

Can dermatology employers require employees to receive the COVID-19 vaccine?

THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS

Expression of retinoid receptors in hand eczema.

S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.

Efficacy and safety of fumaric acid esters in young patients aged 10 to 17 years with moderate-to-severe plaque psoriasis – A randomised, double-blinded, placebo-controlled trial.